Imperative Care, a developer of thrombectomy systems for ischemic stroke and vascular thrombectomy, has raised $100M in oversubscribed convertible note debt financing co-led by Elevage Medical Technologies and Perceptive Advisors with participation from Catalio Capital Management. The company's platforms, including the Zoom Stroke System and Symphony Thrombectomy System, enable fast clot removal via aspiration techniques. The capital will support commercialization of existing portfolios, development of next-gen products like the Telos robotic platform, and clinical evidence generation.
Thrombectomy Acquisitions Heat Up Market
The raise arrives amid massive M&A in thrombectomy, where Stryker acquired Inari Medical for $4.9B in January 2025 and Boston Scientific announced a $14.5B deal for Penumbra in January 2026 per Fierce Biotech. Imperative Care's debt provides non-dilutive fuel to scale independently against these consolidated giants. Its dual focus on neurovascular stroke and peripheral VTE/PE differentiates from Inari's VTE-only emphasis.
Blood Clots Claim 100K US Lives Yearly
Blood clots affect 900,000 Americans annually, claiming 100,000 lives, with ischemic stroke and pulmonary embolism among top killers. Current solutions often involve stent retrievers or incomplete aspiration, leading to reperfusion delays. Mechanical thrombectomy proves superior, but access and speed gaps persist in medium vessels and distal occlusions.
Zoom System Speeds Stroke Reperfusion
Imperative Care's Zoom Stroke System integrates access catheters like Zoom 88 with aspiration tools supporting Continuous Dual Aspiration Technique (CDAT) via DuoPort, achieving fastest median reperfusion times in the Imperative Trial. Symphony delivers large-bore continuous vacuum for PE/VTE, reducing clot burden by 38.4% in the SYMPHONY-PE IDE study. Prodigy targets acute limb ischemia.
As Fred Khosravi, Chairman and CEO, noted:
"This financing is a reflection of the strong momentum we have built and the confidence our investors — new and existing — have in our vision."
Debt Signals Strategic Investor Backing
New investors like Elevage (with CEO Evan Melrose joining the board) and Perceptive bring medtech growth expertise, alongside Catalio and others. Existing backers Ally Bridge Group and Bain Capital Life Sciences signal sustained conviction. Convertible note structure offers flexibility for robotics push without equity dilution amid hot M&A.
Neurovascular Market Grows to $7.2B
The neurovascular devices market stands at $4.27B in 2024, projected to reach $7.22B by 2030 at 9.3% CAGR per MarketsandMarkets. Thrombectomy demand surges with aging populations and expanded treatment windows. Competitors like Route 92 Medical ($167M raised) focus on access, while Stryker and Penumbra dominate retrievers.
Penumbra reported $1.4B revenue in 2025 before its acquisition. Imperative Care's aspiration-centric, full-journey platforms position it for robotics integration.
Serial Entrepreneur Drives Medtech Exits
Co-founder Fred Khosravi, via Incept LLC, has launched 23 medtech companies with 16 exits, holding 200+ patents. Late co-founder L. Nelson Hopkins, MD, pioneered endovascular neurointervention. Recent hires include ex-Auris CTO Richard Leparmentier for robotics and COO Chuck Alpuche with 40+ years experience.
Scaling Via Robotics and Hiring
Funds target Telos robotic platform commercialization to broaden thrombectomy access. Imperative Care plans engineering, R&D, marketing, and physician education hires. Products have reached 78,000+ procedures globally, building on 10,000+ stroke cases by 2022.